{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicby62imrfsjqjg5gnqvwq6tv4p6loq5megosbs3uklvsrv64ypfe",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3moz7i6loqop2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifhvimttuwyyx5xvphsgcqdojjj2fxforrdrectx3nidjmuv5xx6i"
    },
    "mimeType": "image/jpeg",
    "size": 157197
  },
  "path": "/2026/06/23/biotech-news-why-did-one-person-get-special-retatrutide-access-eli-lilly/?utm_campaign=rss",
  "publishedAt": "2026-06-23T13:06:24.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "The \"triple-G\" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout",
  "title": "STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program",
  "updatedAt": "2026-06-23T13:06:29.000Z"
}